I'm in absolutely full agreement with you, Celtics, on the importance of the $4M LOC made available by Triumph. That is a key issue – on exactly what terms and conditions an expanding company can secure funding. The extent of the turnaround is made clear by that test: as you put it, "a thorough examination" followed by an entirely positive conclusion. It's not only a matter of seeing a double and more from those lows in the 8s, but the fact that the SCRC chart has shown its ability to break one resistance level after another – in this case the break about 17. I believe that bodes very well for the whole of this quarter.

More in general, it was good over this weekend to read all the recent posts, from many of the core members, including your overview. What we have seen recently can, in any case, be interpreted as a vindication of the policies and leadership of the CEO, in the first place his seizing of a series of opportunities in pharmacy compounding. The resounding success there has accounted for most of the rising revenue stream, and that still leaves open the possibility of new dimensions in Asia. If, by any chance, clearance comes from the Chinese authorities in Q1 or Q2. If that happened, the future of Scrips would suddenly become even more attractive, but thenI know you are keen to see the company grow one step at a time, one revenue result after another. I added a few for good measure just after today's open, because there is so much upside, and the naysayers have, IMO, completely run out of ammo.